Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT07478848
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Diffuse Large B Cell Lymphoma Refractory
  • Diffuse Large B Cell Lymphoma Relapsed
  • Large B Cell Lymphoma
  • Non Hodgkin Lymphoma (NHL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vancomycin 125mg — DRUG
    oral
  • Radiation Therapy — RADIATION
    Radiation Therapy
  • CAR-T — BIOLOGICAL
    standard of care anti-CD19 CAR-T

Study Details

This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas

Key Dates

Start date
May 27, 2026
Status verified
May 2026
Primary completion
Jan 1, 2029
Completion
Jan 1, 2029

Study Design

Enrollment
14 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: vancomycin, radiation therapy, and CAR-T
    vancomycin 125 mg orally four times per day, followed by standard of care radiation and standard of care CD19 CAR T-cells

Primary Outcome Measure

Cytokine release syndrome [ Time Frame: date of CAR-T infusion to 28 days after infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center, University of PennsylvaniaPhiladelphiaPennsylvania19104
Brittany Koch
[email protected]
215-615-5858

Find similar trials in Philadelphia, PA

By research site
Abramson Cancer Center, University of Pennsylvania· Philadelphia, PA

Related Studies